Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165HOSAKA, Yoshitaka; MATSUMOTO, Miwa; ISHII, Hidemi et al.European journal of pharmacology. 2006, Vol 529, Num 1-3, pp 164-171, issn 0014-2999, 8 p.Article

Future of Anticoagulant TherapyHARENBERG, Job; WEHLING, Martin.Cardiovascular therapeutics (Print). 2011, Vol 29, Num 5, pp 291-300, issn 1755-5914, 10 p.Article

New anticoagulants - promising and failed developmentsHARENBERG, Job; MARX, Svetlana; KREJCZY, Martin et al.British journal of pharmacology. 2012, Vol 165, Num 2, pp 363-372, issn 0007-1188, 10 p.Article

Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjectsKADOKURA, Takeshi; TANIUCHI, Yuta; INOUE, Hiroshi et al.International journal of clinical pharmacology and therapeutics. 2013, Vol 51, Num 3, pp 200-206, issn 0946-1965, 7 p.Article

The direct factor Xa inhibitor rivaroxabanVERMA, Abhishek K; BRIGHTON, Timothy A.Medical journal of Australia. 2009, Vol 190, Num 7, pp 379-383, issn 0025-729X, 5 p.Article

Role of Novel and Emerging Oral Anticoagulants for Secondary Prevention of Acute Coronary SyndromesGANETSKY, Valerie S; HADLEY, Diane E; THOMAS, Tyan F et al.Pharmacotherapy. 2014, Vol 34, Num 6, pp 590-604, issn 0277-0008, 15 p.Article

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjectsXIA ZHAO; PEIHONG SUN; YING ZHOU et al.British journal of clinical pharmacology. 2009, Vol 68, Num 1, pp 77-88, issn 0306-5251, 12 p.Article

Determination of rivaroxaban-a novel, oral, direct Factor Xa inhibitor -in human plasma by high-performance liquid chromatography-tandem mass spectrometryROHDE, G.Journal of chromatography. B. 2008, Vol 872, Num 1-2, pp 43-50, issn 1570-0232, 8 p.Article

Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitorIWATSUKI, Yoshiyuki; SATO, Takayuki; MORITANI, Yumiko et al.European journal of pharmacology. 2011, Vol 673, Num 1-3, pp 49-55, issn 0014-2999, 7 p.Article

Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxabanHARENBERG, Job; MARX, Svetlana; KRÄMER, Roland et al.Blood coagulation & fibrinolysis. 2011, Vol 22, Num 8, pp 637-641, issn 0957-5235, 5 p.Article

Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjectsKADOKURA, Takeshi; KASHIWA, Makoto; GROENENDAAL, Dorien et al.Biopharmaceutics & drug disposition. 2013, Vol 34, Num 8, pp 431-441, issn 0142-2782, 11 p.Article

Rivaroxaban : an oral, direct Factor Xa inhibitor -has potential for the management of patients with heparin-induced thrombocytopeniaWALENGA, Jeanine M; PRECHEL, Margaret; JESKE, Walter P et al.British journal of haematology. 2008, Vol 143, Num 1, pp 92-99, issn 0007-1048, 8 p.Article

Old Versus New Oral Anticoagulants: Focus on PharmacologyFAREED, Jawed; THETHI, Indermohan; HOPPENSTEADT, Debra et al.Annual review of pharmacology and toxicology (Print). 2012, Vol 52, pp 79-99, issn 0362-1642, 21 p.Article

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Major Orthopedic SurgeryMELILLO, Stephanie N; SCANLON, James V; EXTER, Benjamin P et al.The Annals of pharmacotherapy. 2010, Vol 44, Num 6, pp 1061-1071, issn 1060-0280, 11 p.Article

Rivaroxaban: Practical Considerations for Ensuring Safety and EfficacySMYTHE, Maureen A; FANIKOS, John; GULSETH, Michael P et al.Pharmacotherapy. 2013, Vol 33, Num 11, pp 1223-1245, issn 0277-0008, 23 p.Article

The in vitro anticoagulant effect of rivaroxaban in childrenATTARD, C; MONAGLE, P; KUBITZA, D et al.Thrombosis research. 2012, Vol 130, Num 5, pp 804-807, issn 0049-3848, 4 p.Article

Does a longer duration of oral factor Xa therapy increase the risk of bleeding or transaminitis?FROM, Aaron M; HOGANSON, Deana D; ERWIN, Patricia J et al.Thrombosis research. 2011, Vol 127, Num 3, pp 202-209, issn 0049-3848, 8 p.Article

Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor XaLOPOPOLO, Gianfranco; FIORELLA, Filomena; DE CANDIA, Modesto et al.European journal of pharmaceutical sciences. 2011, Vol 42, Num 3, pp 180-191, issn 0928-0987, 12 p.Article

New Antithrombotics for Atrial FibrillationBEREZNICKI, Luke R. E; PETERSON, Gregory M.Cardiovascular therapeutics (Print). 2010, Vol 28, Num 5, pp 278-286, issn 1755-5914, 9 p.Article

New Anticoagulants in Atrial FibrillationHARENBERG, Job.Seminars in thrombosis and hemostasis. 2009, Vol 35, Num 6, pp 574-585, issn 0094-6176, 12 p.Article

Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic additives in its oral dosage formFUJII, Yoshimine; KANAMARU, Taro; KIKUCHI, Hiroshi et al.International journal of pharmaceutics (Print). 2011, Vol 421, Num 2, pp 244-251, issn 0378-5173, 8 p.Article

Rivaroxaban : A Novel, Oral, Direct Factor Xa InhibitorABRAMS, Paris J; EMERSON, Christopher R.Pharmacotherapy. 2009, Vol 29, Num 2, pp 167-181, issn 0277-0008, 15 p.Article

In Vitro Effects of Argatroban, Lepirudin, Bivalirudin, and Danaparoid on Fibrin Gel PermeabilitySHU HE; WALLEN, Hakan; JOHNSSON, Hans et al.Seminars in thrombosis and hemostasis. 2008, Vol 34, pp 91-96, issn 0094-6176, 6 p., SUP1Article

Inaccuracy of Point-of-Care International Normalized Ratio in Rivaroxaban-Treated PatientsBARUCH, Lawrence; SHERMAN, Olga.The Annals of pharmacotherapy. 2013, Vol 47, Num 9, pp 1210-1212, issn 1060-0280, 3 p.Article

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorKUBITZA, Dagmar; BECKA, Michael; MUECK, Wolfgang et al.British journal of clinical pharmacology. 2010, Vol 70, Num 5, pp 703-712, issn 0306-5251, 10 p.Article